Biocon Biologics gets US nod to launch Stelara biosimilar

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions like Crohn's disease and plaque psoriasis. Despite competition from five other biosimilars, this launch is anticipated to significantly boost Biocon’s revenue and profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0cAdEu
via IFTTT